RxDoctor Payments Data

Jessica Taff, MD

Hematology · Toms River, NJNPI 1679866214

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $452 of the $571 with a category attached, or 79.2%. 9 manufacturers reported payments, led by Daiichi Sankyo Inc. at 40.4% of the total. Reporting peaked in 2019 at $209 and has fallen 67.8% since, to $68 in 2025. That places this record below the midpoint for hematology clinicians in NJ, where the typical reported total is $2,217.

$571in general payments, 2019–2025

Across 43 payments — averaging $13.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$230
  • Johnson & Johnson$174
  • Regeneron Healthcare Solutions, Inc.$51
  • Lilly USA, LLC$29
  • Merck$27
  • Roche Diagnostics Corporation$15
  • plus $44 from 3 others

What the payments were for

  • Food & beverage$45279%
  • Education$11921%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$571 in reported general payments places this provider in the 30th percentile of 43 hematology providers in New Jersey.

See all hematology providers in New Jersey

Medicare billing

Part B allowed, 2024
$219,958
Medicare patients
442
Services billed
1,817

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate46$613,802
BosulifBosutinib22$405,497
JakafiRuxolitinib Phosphate20$346,081
CabometyxCabozantinib S-Malate11$258,144
LumakrasSotorasib12$193,842
EliquisApixaban89$86,909
Abiraterone Acetate31$53,025
XareltoRivaroxaban15$18,310
Dabigatran EtexilateDabigatran Etexilate Mesylate16$3,883
Anastrozole147$3,181
Fentanyl29$2,102
Hydroxyurea45$1,979
Exemestane22$1,641
Letrozole45$829
Tamoxifen Citrate35$806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$15$613,80246 claims
Johnson & JohnsonXarelto$174$18,31015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 43 hematology providers in New Jersey.

Other hematology in Toms River

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →